Tekla Total Stockholder Equity vs Accounts Payable Analysis

HQL Stock

USD 13.47 0.13 0.96%

Tekla Life financial indicator trend analysis is much more than just breaking down Tekla Life Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tekla Life Sciences is a good investment. Please check the relationship between Tekla Life Total Stockholder Equity and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.

Total Stockholder Equity vs Accounts Payable

Total Stockholder Equity vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tekla Life Sciences Total Stockholder Equity account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Tekla Life's Total Stockholder Equity and Accounts Payable is 0.49. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Tekla Life Sciences, assuming nothing else is changed. The correlation between historical values of Tekla Life's Total Stockholder Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Tekla Life Sciences are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Stockholder Equity i.e., Tekla Life's Total Stockholder Equity and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.49

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Accounts Payable

An accounting item on the balance sheet that represents Tekla Life obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Tekla Life Sciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Tekla Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tekla Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.

At this time, Tekla Life's Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 18.05 this year, although the value of Selling General Administrative will most likely fall to about 692 K.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	1.4M	1.2M	1.3M	861.3K
Cost Of Revenue	5.5M	5.2M	6.0M	3.9M

Total Operating Expenses Cost Of Revenue

Tekla Life fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Common Stock	Net Receivables	Other Stockholder Equity	Net Tangible Assets	Retained Earnings	Long Term Investments	Other Liab	Other Current Assets	Short Term Investments	Capital Stock	Non Current Liabilities Total
Total Assets		0.17	0.51	1.0	0.3	0.5	-0.22	1.0	-0.96	-0.7	0.21	0.08	0.81	0.33	0.2	0.08	0.2	0.29	0.75	0.15	0.73	0.7	-0.09	0.24	-0.33	0.18
Other Current Liab	0.17		0.25	0.17	0.35	-0.22	-0.14	0.18	-0.23	0.07	0.12	0.0	-0.18	0.19	-0.32	0.0	-0.31	-0.14	0.36	0.51	0.4	-0.14	0.15	-0.18	0.06	0.75
Total Current Liabilities	0.51	0.25		0.49	0.01	0.71	0.18	0.52	-0.46	-0.25	-0.25	-0.44	0.6	0.6	0.1	-0.44	0.11	0.61	0.34	-0.19	0.39	0.32	-0.54	0.68	-0.62	0.47
Total Stockholder Equity	1.0	0.17	0.49		0.31	0.49	-0.23	1.0	-0.96	-0.7	0.22	0.09	0.8	0.3	0.21	0.09	0.21	0.28	0.76	0.15	0.73	0.7	-0.07	0.21	-0.31	0.15
Net Debt	0.3	0.35	0.01	0.31		0.33	-0.97	0.31	-0.33	-0.1	0.84	-0.45	0.17	-0.01	-0.26	-0.45	-0.23	0.38	0.38	0.26	0.4	0.07	-0.06	0.01	-0.47	-0.11
Accounts Payable	0.5	-0.22	0.71	0.49	0.33		-0.28	0.5	-0.47	-0.33	0.2	-0.62	0.71	0.36	0.22	-0.62	0.24	0.87	0.31	-0.41	0.35	0.35	-0.63	0.71	-0.86	-0.16
Cash	-0.22	-0.14	0.18	-0.23	-0.97	-0.28		-0.23	0.24	0.08	-0.88	0.39	-0.13	0.13	0.21	0.39	0.18	-0.32	-0.28	-0.21	-0.29	-0.06	0.0	0.06	0.39	0.31
Non Current Assets Total	1.0	0.18	0.52	1.0	0.31	0.5	-0.23		-0.96	-0.69	0.22	0.06	0.8	0.34	0.17	0.06	0.17	0.29	0.76	0.15	0.74	0.69	-0.1	0.25	-0.33	0.18
Non Currrent Assets Other	-0.96	-0.23	-0.46	-0.96	-0.33	-0.47	0.24	-0.96		0.7	-0.24	-0.1	-0.69	-0.37	-0.15	-0.1	-0.15	-0.25	-0.75	-0.19	-0.73	-0.57	0.06	-0.2	0.3	-0.23
Other Assets	-0.7	0.07	-0.25	-0.7	-0.1	-0.33	0.08	-0.69	0.7		-0.06	-0.13	-0.68	-0.16	-0.21	-0.13	-0.21	-0.22	-0.78	-0.28	-0.74	-0.88	0.15	-0.22	0.22	0.03
Cash And Short Term Investments	0.21	0.12	-0.25	0.22	0.84	0.2	-0.88	0.22	-0.24	-0.06		-0.17	0.14	-0.18	-0.22	-0.17	-0.23	0.17	0.17	0.05	0.19	0.02	-0.04	-0.08	-0.24	-0.31
Common Stock Total Equity	0.08	0.0	-0.44	0.09	-0.45	-0.62	0.39	0.06	-0.1	-0.13	-0.17		-0.22	-0.22	0.27	1.0	0.23	-0.88	0.01	0.37	-0.11	0.04	0.7	-0.64	0.89	0.1
Common Stock Shares Outstanding	0.81	-0.18	0.6	0.8	0.17	0.71	-0.13	0.8	-0.69	-0.68	0.14	-0.22		0.32	0.35	-0.22	0.35	0.59	0.51	-0.24	0.53	0.8	-0.51	0.61	-0.6	-0.09
Total Liab	0.33	0.19	0.6	0.3	-0.01	0.36	0.13	0.34	-0.37	-0.16	-0.18	-0.22	0.32		-0.17	-0.22	-0.17	0.28	0.11	-0.05	0.2	0.1	-0.45	0.69	-0.34	0.68
Total Current Assets	0.2	-0.32	0.1	0.21	-0.26	0.22	0.21	0.17	-0.15	-0.21	-0.22	0.27	0.35	-0.17		0.27	1.0	0.03	0.03	-0.19	-0.1	0.23	0.04	-0.01	0.03	-0.29
Common Stock	0.08	0.0	-0.44	0.09	-0.45	-0.62	0.39	0.06	-0.1	-0.13	-0.17	1.0	-0.22	-0.22	0.27		0.23	-0.88	0.01	0.37	-0.11	0.04	0.7	-0.64	0.89	0.1
Net Receivables	0.2	-0.31	0.11	0.21	-0.23	0.24	0.18	0.17	-0.15	-0.21	-0.23	0.23	0.35	-0.17	1.0	0.23		0.06	0.04	-0.17	-0.08	0.23	0.05	-0.01	0.0	-0.3
Other Stockholder Equity	0.29	-0.14	0.61	0.28	0.38	0.87	-0.32	0.29	-0.25	-0.22	0.17	-0.88	0.59	0.28	0.03	-0.88	0.06		0.23	-0.47	0.33	0.28	-0.79	0.77	-0.99	-0.18
Net Tangible Assets	0.75	0.36	0.34	0.76	0.38	0.31	-0.28	0.76	-0.75	-0.78	0.17	0.01	0.51	0.11	0.03	0.01	0.04	0.23		0.46	0.97	0.71	0.08	0.0	-0.25	0.18
Retained Earnings	0.15	0.51	-0.19	0.15	0.26	-0.41	-0.21	0.15	-0.19	-0.28	0.05	0.37	-0.24	-0.05	-0.19	0.37	-0.17	-0.47	0.46		0.38	0.16	0.57	-0.52	0.41	0.34
Long Term Investments	0.73	0.4	0.39	0.73	0.4	0.35	-0.29	0.74	-0.73	-0.74	0.19	-0.11	0.53	0.2	-0.1	-0.11	-0.08	0.33	0.97	0.38		0.67	-0.06	0.13	-0.36	0.23
Other Liab	0.7	-0.14	0.32	0.7	0.07	0.35	-0.06	0.69	-0.57	-0.88	0.02	0.04	0.8	0.1	0.23	0.04	0.23	0.28	0.71	0.16	0.67		-0.19	0.27	-0.27	-0.1
Other Current Assets	-0.09	0.15	-0.54	-0.07	-0.06	-0.63	0.0	-0.1	0.06	0.15	-0.04	0.7	-0.51	-0.45	0.04	0.7	0.05	-0.79	0.08	0.57	-0.06	-0.19		-0.93	0.79	-0.02
Short Term Investments	0.24	-0.18	0.68	0.21	0.01	0.71	0.06	0.25	-0.2	-0.22	-0.08	-0.64	0.61	0.69	-0.01	-0.64	-0.01	0.77	0.0	-0.52	0.13	0.27	-0.93		-0.78	0.15
Capital Stock	-0.33	0.06	-0.62	-0.31	-0.47	-0.86	0.39	-0.33	0.3	0.22	-0.24	0.89	-0.6	-0.34	0.03	0.89	0.0	-0.99	-0.25	0.41	-0.36	-0.27	0.79	-0.78		0.12
Non Current Liabilities Total	0.18	0.75	0.47	0.15	-0.11	-0.16	0.31	0.18	-0.23	0.03	-0.31	0.1	-0.09	0.68	-0.29	0.1	-0.3	-0.18	0.18	0.34	0.23	-0.1	-0.02	0.15	0.12

Click cells to compare fundamentals

Tekla Life Account Relationship Matchups

Tekla Life fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	484.2M	534.2M	414.7M	402.6M	463.0M	335.6M
Other Current Liab	(2.8M)	567.3K	10.7M	(5.1M)	(5.9M)	(5.6M)
Total Current Liabilities	2.8M	581.2K	10.7M	5.1M	5.9M	3.2M
Total Stockholder Equity	483.6M	523.4M	397.9M	401.9M	462.2M	332.0M
Net Debt	5.0M	1.3M	10.6K	(477.0)	(548.55)	(575.98)
Cash	(5.0M)	990.0	445.0	477.0	429.3	407.84
Non Current Assets Total	484.0M	534.0M	414.1M	397.5M	457.2M	332.8M
Non Currrent Assets Other	(484.0M)	(534.0M)	(414.1M)	(397.5M)	(357.8M)	(375.7M)
Other Assets	118.6K	33.0K	25.4K	26.3K	23.7K	22.5K
Cash And Short Term Investments	5.0M	990.0	445.0	477.0	548.55	521.12
Common Stock Shares Outstanding	23.8M	24.3M	25.7M	26.8M	30.8M	19.2M
Liabilities And Stockholders Equity	484.2M	534.2M	414.7M	402.6M	463.0M	335.6M
Total Liab	595.2K	10.7M	16.8M	667.0K	767.0K	728.7K
Total Current Assets	73.9K	144.7K	623.9K	5.0M	5.8M	6.1M
Common Stock	238.8K	246.7K	256.8K	267.9K	308.1K	292.7K
Net Receivables	73.9K	143.7K	623.5K	5.0M	5.8M	6.1M
Other Stockholder Equity	356.3M	372.5M	388.1M	403.1M	463.6M	486.8M
Net Tangible Assets	383.7M	483.6M	523.4M	397.9M	457.6M	449.7M
Retained Earnings	127.0M	150.7M	9.5M	(1.5M)	(1.7M)	(1.6M)
Long Term Investments	484.0M	534.0M	414.1M	397.5M	457.2M	444.7M
Other Current Assets	(5.0M)	(17.3M)	(33.6M)	(20.3M)	(18.3M)	(17.3M)
Short Term Investments	5.0M	17.2M	32.9M	15.2M	17.5M	12.9M
Capital Stock	238.8K	246.7K	256.8K	267.9K	241.1K	229.1K
Non Current Liabilities Total	569.2K	9.4M	5.1M	667.0K	600.3K	570.3K

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Tekla Life Sciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Tekla Life Sciences is a strong investment it is important to analyze Tekla Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tekla Life's future performance. For an informed investment choice regarding Tekla Stock, refer to the following important reports:

How To Invest In Tekla

Details

Is Tekla Stock a good investment?

Details

What is Tekla Life's Net Worth?

Details

Largest Asset Management & Custody Banks Companies

View

Largest Financial Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Tekla Stock analysis

When running Tekla Life's price analysis, check to measure Tekla Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tekla Life is operating at the current time. Most of Tekla Life's value examination focuses on studying past and present price action to predict the probability of Tekla Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tekla Life's price. Additionally, you may evaluate how the addition of Tekla Life to your portfolios can decrease your overall portfolio volatility.

	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Transaction History View history of all your transactions and understand their impact on performance
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Commodity Directory Find actively traded commodities issued by global exchanges
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas

Is Tekla Life's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.66)

Dividend Share

1.3

Earnings Share

0.79

Revenue Per Share

0.134

Quarterly Revenue Growth

0.344

The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tekla Total Stockholder Equity vs Accounts Payable Analysis

Total Stockholder Equity vs Accounts Payable

Total Stockholder Equity vs Accounts Payable Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Accounts Payable

Tekla Life fundamental ratios Correlations

Tekla Life Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tekla Life fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Tekla Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Net Receivables	+ 1.0	Total Current Assets
Long Term Investments	+ 0.97	Net Tangible Assets

Capital Stock	- 0.99	Other Stockholder Equity
Cash	- 0.97	Net Debt
Non Currrent Assets Other	- 0.96	Non Current Assets Total
Non Currrent Assets Other	- 0.96	Total Stockholder Equity
Non Currrent Assets Other	- 0.96	Total Assets
Short Term Investments	- 0.93	Other Current Assets